Literature DB >> 11567745

Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus.

S Finerty1, C R Stokes, T J Gruffydd-Jones, T J Hillman, F J Barr, D A Harbour.   

Abstract

With the rapid spread of human immunodeficiency virus (HIV) infection worldwide it is clear that effective strategies for mucosal vaccination against lentiviruses are urgently required. The aim of the present study is to determine whether protective immune responses against a mucosal challenge by feline immunodeficiency virus (FIV) can be elicited by targeting the immunization to the medial iliac lymph nodes--the principal site of migration of cells from the genital and rectal mucosa. Cats were challenged with homologous FIV via the rectal route. Targeted lymph node immunization was found to be an effective route of immunization eliciting both humoral and proliferative responses to peptide-based and fixed cell vaccines. Vaccination with fixed virus infected cells elicited protection against a cell-free mucosal FIV challenge. In addition, some cats vaccinated with fixed uninfected cells also remained uninfected following a cell-associated FIV challenge.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567745     DOI: 10.1016/s0264-410x(01)00323-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Introduction: a welcome to the First Special Animal Health Issue of AAPS PharmSci.

Authors:  Marilyn Martinez; Stefan Soback
Journal:  AAPS PharmSci       Date:  2002

Review 2.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Major Histocompatibility Complex Class I (FLA-E*01801) Molecular Structure in Domestic Cats Demonstrates Species-Specific Characteristics in Presenting Viral Antigen Peptides.

Authors:  Ruiying Liang; Yaping Sun; Yanjie Liu; Junya Wang; Yanan Wu; Zibin Li; Lizhen Ma; Nan Zhang; Lijie Zhang; Xiaohui Wei; Zehui Qu; Nianzhi Zhang; Chun Xia
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

4.  Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.

Authors:  Sunil K Khattar; Sweety Samal; Anthony L Devico; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.

Authors:  M Magdalena Gherardi; José Luis Nájera; Eva Pérez-Jiménez; Susana Guerra; Adolfo García-Sastre; Mariano Esteban
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Mucosal challenge with cell-associated or cell-free feline immunodeficiency virus induces rapid and distinctly different patterns of phenotypic change in the mucosal and systemic immune systems.

Authors:  Kristina E Howard; Mary Jo Burkhard
Journal:  Immunology       Date:  2007-07-16       Impact factor: 7.397

9.  Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial.

Authors:  Gabriela Senti; Bettina M Prinz Vavricka; Iris Erdmann; Mella I Diaz; Richard Markus; Stephen J McCormack; John J Simard; Brunello Wüthrich; Reto Crameri; Nicole Graf; Pål Johansen; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-10       Impact factor: 11.205

10.  Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.

Authors:  Anthony D Cristillo; Maria Grazia Ferrari; Lauren Hudacik; Brad Lewis; Lindsey Galmin; Britany Bowen; DeVon Thompson; Nikolai Petrovsky; Phillip Markham; Ranajit Pal
Journal:  J Gen Virol       Date:  2011-01       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.